Zebrafish models of Mucopolysaccharidosis types IIIA, B, & C show hyperactivity and changes in oligodendrocyte state

Ewan Gerken,Syahida Ahmad,Lakshay Rattan,Kim M Hemsley,Shijin Suo,Karissa Barthelson,Michael Lardelli
DOI: https://doi.org/10.1101/2023.08.02.550904
2024-10-30
Abstract:Sanfilippo syndrome childhood dementia, also known as mucopolysaccharidosis type III (MPS III), is a rare inherited lysosomal storage disorder. Subtypes of MPS III are caused by deficiencies in one of four enzymes required for degradation of the glycosaminoglycan heparan sulfate (HS). An inability to degrade HS leads to progressive neurodegeneration and death in the second or third decades of life. Knowledge of MPS III pathogenesis is incomplete, and no effective therapies exist. We generated the hypomorphic mutations , and in the endogenous zebrafish genes orthologous to human , , and that are loci for mutations causing MPS III subtypes MPS IIIA, B and C respectively. Our models display the primary MPS III disease signature of significant brain accumulation of HS, while behavioural analyses support anxiety and hyperactivity phenotypes. Brain transcriptome analysis revealed changes related to lysosomal, glycosaminoglycan, immune system and iron homeostasis biology in all three models but also distinct differences in brain transcriptome state between models. The transcriptome analysis also indicated marked disturbance of the oligodendrocyte cell state in the brains of MPS IIIA, B and C zebrafish, supporting that effects on this cell type are an early and consistent characteristic of MPS III. Overall, our zebrafish models recapture key characteristics of the human disease and phenotypes seen in mouse models. Our models will allow exploitation of the zebrafishs extreme fecundity and accessible anatomy to dissect the pathological mechanisms both common and divergent between the MPS IIIA, B, and C subtypes.
Neuroscience
What problem does this paper attempt to address?
The problem that this paper attempts to solve is related to Mucopolysaccharidosis Type III (MPS III), also known as Sanfilippo syndrome, which is a rare hereditary lysosomal storage disorder. MPS III is divided into four subtypes (A, B, C, D), and each subtype is caused by the loss of function of one of the four different enzymes required for the degradation of heparan sulfate (HS). Due to the inability to degrade HS, it leads to the gradual degeneration of the nervous system and eventually death within the second or third decade of the patient's life. Currently, the understanding of the pathological mechanism of MPS III is incomplete, and there are no effective treatment methods. In order to better understand the pathological mechanism of MPS III and develop new treatment strategies, the authors used CRISPR - Cas9 gene - editing technology to generate mutant models of three subtypes of MPS IIIA, IIIB, and IIIC in zebrafish. These models exhibit key features of the human disease, such as significant accumulation of HS in the brain, as well as anxious and hyperactive phenotypes in behavior. Through brain transcriptome analysis, the researchers found that there are alterations related to lysosomes, glycosaminoglycans, the immune system, and iron homeostasis biology in all three models, but there are also significant differences in the brain transcriptome states between different models. In particular, transcriptome analysis shows that the state of oligodendrocytes in the brains of MPS IIIA, IIIB, and IIIC zebrafish has changed significantly, indicating that this cell type is particularly sensitive to the influence of MPS III. Overall, these zebrafish models reproduce the key features of the human disease, providing a valuable tool for studying the pathophysiological mechanism of MPS III and can be used to test new treatment strategies.